Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma

PURPOSE: Anaplastic large cell lymphoma (ALCL) is a rare aggresive non-Hodgkin lymphoma, of which over 50% of cases have an aberrant nucleophosmin (NPM)‒anaplastic lymphoma kinase (ALK) fusion protein. Both mechanistic target of rapamycin (mTOR) inhibitor everolimus and ALK inhibitor crizotinib have...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Wendan, Kim, Ji-Won, Jung, Woo June, Koh, Youngil, Yoon, Sung-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5912135/
https://www.ncbi.nlm.nih.gov/pubmed/28675026
http://dx.doi.org/10.4143/crt.2016.357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5912135/
https://www.ncbi.nlm.nih.gov/pubmed/28675026
http://dx.doi.org/10.4143/crt.2016.357

Ejemplares similares